Video
David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments.
Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…
The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.
Celine Druart, from the Pharmabiotic Research Institute, highlighted critical challenges in the microbiome field, particularly around the standardization of clinical protocols and analytical methods.
Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors.
Nicola Segata, from University of Trento, investigates the intricate links between diet, microbiome composition, and cardiometabolic outcomes.
Clara Delaroque, from Institut Pasteur (France), emphasizes the critical interplay between early-life microbiota and host health, specifically how the use of common food additives impacts the susceptibility to diseases later…
Raphaëlle Bourdet-Sicard from Danone Nutricia Research discusses a study which investigates the use of a mixed prebiotic formulation to enhance iron absorption while mitigating adverse effects on gut microbiota.
Professor Maria Rescigno explores the critical role of the gut microbiota in maintaining intestinal barrier integrity and its implications for health.
Nathalie Maria Delzenne from Université Catholique de Louvain (Belgium) explains how gut microbiota and systemic inflammation impact cravings and depressive symptoms in affected individuals.
